Watson sues US FDA over generic Actos exclusivity denial
This article was originally published in Scrip
The US FDA has refused to grant shared exclusivity to Watson Pharmaceuticals for its generic version of the Type II diabetes agent pioglitazone – "unnecessarily" delaying the launch of the drug by up to six months, causing "potential harm to consumers who may face constraints on supply as a result of this action," the company is charging in a lawsuit filed against the agency.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.